At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 451 enrolled
Drug / intervention
Valsartan/aliskiren +1 moredrug
Likely dose
Valsartan/aliskiren 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An 8-week Randomized, Double-Blind, Parallel Group, Multi-Center, Active Controlled Study to Evaluate the Efficacy and Safety of Valsartan Administered in Combination With Aliskiren (160/150 mg, 320/300 mg) Versus Valsartan Alone (160 mg, 320 mg) in Patients With Stage 2 Hypertension
In Brief
A Phase 4 clinical trial evaluating Valsartan/aliskiren and Valsartan for Stage 2 Hypertension. Completed, enrolled 451 participants across 1 site.
Detailed Summary
To evaluate the efficacy and safety of the valsartan/aliskiren combination compared to valsartan alone in patients with Stage 2 hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStage 2 Hypertension
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartJan 2009
Primary CompletionJul 2009
TodayJul 2026
First PostedDec 17, 2008
Enrollment StartJan 1, 2009
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 17.5 years ago
Interventions
Valsartan/aliskirendrug
Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
Valsartandrug
Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks